Combination Immune Checkpoint Inhibitor Therapy is Associated With Increased Blood Pressure in Melanoma Patients.

HomeHypertensionVol. 80, No. 3Combination Immune Checkpoint Inhibitor Therapy is Associated With Increased Blood Pressure in Melanoma Patients No AccessLetterRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessLetterRequest AccessFull TextCombination Immune Checkpoint Inhibitor Therapy is Associated With Increased Blood Pressure in Melanoma Patients Isik Turker, Ananya Sharma, Shi Huang, Douglas B. Johnson and Matthew R. Alexander Isik TurkerIsik Turker https://orcid.org/0000-0003-3216-3499 Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN (I.T., M.R.A.). Department of Medicine, Division of Cardiology, Washington University School of Medicine, St Louis, MO (I.T.). Search for more papers by this author , Ananya SharmaAnanya Sharma https://orcid.org/0000-0001-6592-5811 Vanderbilt University School of Medicine, Nashville, TN (A.S.). Search for more papers by this author , Shi HuangShi Huang Department of Biostatistics, Vanderbilt University, Nashville, TN (S.H.). Search for more papers by this author , Douglas B. JohnsonDouglas B. Johnson Department of Medicine, Division of Hematology and Oncology, VUMC, Nashville, TN (D.B.J.). Search for more papers by this author and Matthew R. AlexanderMatthew R. Alexander Correspondence to: Matthew R. Alexander, Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, 2215 Garland Ave, 560B RRB Nashville, TN 37232, Email E-mail Address: [email protected] https://orcid.org/0000-0003-4739-7204 Department of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN (I.T., M.R.A.). Department of Medicine, Division of Clinical Pharmacology, VUMC, Nashville, TN (M.R.A.). Vanderbilt Institute for Infection, Immunology, and Inflammation, VUMC, Nashville, TN (M.R.A.). Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN (M.R.A.). Search for more papers by this author Originally published18 Nov 2022https://doi.org/10.1161/HYPERTENSIONAHA.122.20407Hypertension. 2023;80:e43–e45FootnotesFor Sources of Funding and Disclosures, see page e45.Correspondence to: Matthew R. Alexander, Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, 2215 Garland Ave, 560B RRB Nashville, TN 37232, Email matt.[email protected]orgReferences1. Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, Colantinio LD. Trends in blood pressure control among us adults with hypertension, 1999-2000 to 2017-2018.JAMA. 2020; 324:1190–1200. doi: 10.1001/jama.2020.14545CrossrefMedlineGoogle Scholar2. Madhur MS, Elijovich F, Alexander MR, Pitzer A, Ishimwe J, Van Beusecum JP, Patrick DM, Smart CD, Kleyman TR, Kingery J, et al. Hypertension: do inflammation and immunity hold the key to solving this epidemic?Circ Res. 2021; 128:908–933. doi: 10.1161/CIRCRESAHA.121.318052LinkGoogle Scholar3. Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity.Nat Rev Clin Oncol. 2022; 19:254–267. doi: 10.1038/s41571-022-00600-wCrossrefMedlineGoogle Scholar4. Lee J, Lozano-Ruiz B, Yang FM, Fan DD, Shen L, Gonzalez-Navajas J. The Multifaceted role of Th1, Th9, and Th17 cells in immune checkpoint inhibition therapy.Front Immunol. 2021; 12:625–667. doi: 10.3389/fimmu.2021.625667CrossrefGoogle Scholar5. Minegishi S, Kinguchi S, Horita N, Namkoong H, Briasoulis A, Ishivgami T, Tamura K, Nishiyama A, Yano Y; Japanese Society of Hypertension working group “Onco-Hypertension”. Immune checkpoint inhibitors do not increase short-term risk of hypertension in cancer patients: a systematic literature review and meta-analysis.Hypertension. 2022; 79:2611–2621. doi: 10.1161/HYPERTENSIONAHA.122.19865LinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails March 2023Vol 80, Issue 3 Advertisement Article InformationMetrics © 2022 American Heart Association, Inc.https://doi.org/10.1161/HYPERTENSIONAHA.122.20407PMID: 36398660 Originally publishedNovember 18, 2022 Keywordshypertensionimmunotherapyblood pressurecancermelanomaimmune checkpoint inhibitorsPDF download Advertisement SubjectsHigh Blood PressureHypertensionInflammation